source
- Amylyx reports positive pivotal trial results for drug targeting post-bariatric hypoglycemiaAmylyx announced that its experimental therapy achieved statistically significant improvement in patients who experience severe hypoglycemia after bariatric surgery. The company said the pivotal t…
- BioMarin to buy Alesta Therapeutics for $275M, adding rare bone disease drug to pipelineBioMarin announced Tuesday that it will acquire privately held Alesta Therapeutics, paying $275 million upfront with potential additional payments tied to milestones. The deal, expected to close b…